Education

Fellowship
Cytopathology, UCLA School of Medicine, 1999
Residency
Pathology & Laboratory Med., UCLA School of Medicine, 1998
Fellowship
Urology, University of Oklahoma College of Medicine, 1992
Degree
MD, Shanghai Medical University, 1984

Medical Board Certifications

Cytopathology
American Board of Pathology, 2002
Anatomic Pathology & Clinical Pathology
American Board of Pathology, 1998

Gender

Male

State License

A55745
  • About Me

    About Me

    JianYu Rao is an Associate Professor of Pathology and epidemiology. He is a surgical pathologist and cytopathologist specialized in genitourinary tract and gynecological pathology. He is also a molecular epidemiologist and cancer cell biologist.

    He did his training of Anatomic and Clinical pathology as well as Cytopathlogy here at UCLA from 1994 to 1999. He became the faculty at Department of Pathology and Lab Med since 1999.

    He is the director of cytopathology research.

  • Locations

    UCLA Pathology & Lab Medicine

    (primary location)
    Address
    10833 Le Conte Avenue
    Suite 13-188 CHS
    Los Angeles, California 90095
    Phone
    310-825-8940
  • Education

    Medical Board Certifications

    Cytopathology
    American Board of Pathology, 2002
    Anatomic Pathology & Clinical Pathology
    American Board of Pathology, 1998

    Education

    Fellowship
    Cytopathology, UCLA School of Medicine, 1999
    Residency
    Pathology & Laboratory Med., UCLA School of Medicine, 1998
    Fellowship
    Urology, University of Oklahoma College of Medicine, 1992
    Degree
    MD, Shanghai Medical University, 1984
  • Research

    Research Interest

    Develop tools for cancer screening and early detection

    Dr. Rao's lab is interested in developing tools for cancer screening, early detection, and therapeutic monitoring.

    Technical Research Interest:

    Biomarkers for cancer early detection and screening

    The research in my laboratory is focused on developing biomarkers that can be used for individual risk assessment, early detection, and therapeutic monitoring of cancer. To reach this goal, we have two specific research areas.

    The first area of research is to study the molecular basis of tumor morphogenesis, we focus our effort on investigating how cytoskeletal proteins, specifically the microfilament actin and the associated binding proteins, are altered in tumorigenesis. We hypothesize that since tumor cells have morphological features that are distinctive from normal cells, and since actin family proteins play important roles in regulating cell morphology, adhesion, as well as motility, investigating these protein changes during tumorigenesis will not only provide molecular insight for tumor morphology, but at the same time develop surrogate markers that are more sensitive and specific than morphological analysis alone. Since actin network is regulated by multiple complex oncogenic signal transduction events, including Ras superfamily small G proteins Rac/Rho/Cdc42, and Src family proteins, and many of these proteins have been developed as the potential therapeutic targets, it is possible that an actin centric strategy for cancer detection/monitoring/prevention/therapy can be developed in he future.

    Our second area of research is to develop approaches that can be used to detect early malignant lesions, especially cancer of the breast, bladder, and prostate. The detection of low stage malignant and premalignant lesions is essential for the successful halt, or even the reversion of malignant progression through chemoprevention strategy. The focus will be to develop simple, high throughput techniques that can be used to detect expressional abnormalities of multiple genes on a small sample volume basis. One specific example is to develop Quantitative Fluorescence Image Analysis (QFIA) as a single-cell proteomic method for biomarker analysis on cytological materials.

    Publications